-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A new study by the Institute of Psychiatry, Psychology and Neuroscience (IoPPN) at King's College London in collaboration with COMPASS Pathways has confirmed that psilocybin is safe to take in doses of 10mg or 25mg
This is the first thorough study of concomitant administration of psilocybin
Participants were closely monitored for 6 to 8 hours after the psilocybin injection and then followed for 12 weeks
National Institutes of Health Clinical Scientist Dr James Lack, lead author of the study, IoPPN from King's College, and Honorary Psychiatric Consultant at the NHS Foundation South London and Maudsley, said: "This rigorous research is important This is the first demonstration that simultaneous administration of psilocybin can be further explored
Professor Guy Goodwin, Chief Medical Officer at COMPASS Pathways, said: "This study is an early part of our clinical development programme for the COMP360 psilocybin treatment
Researchers have completed a Phase 2 study exploring the efficacy and safety of psilocybin in patients with TRD and PTSD, and are analyzing the data